Lentiviral calnexin-modified dendritic cells promote expansion of high-avidity effector T cells with central memory phenotype

Immunology

Volumn 128, Issue 1, 2009, Pages 43-57

  Wang, Bei ^b   Han, Shuhong ^b   Lien, Lily ^c   Chang, Lung Ji ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Vectorite Biomedica Inc   (Taiwan)

Author keywords

Antigen presentation; Calnexin; Cytotoxic T cells; Dendritic cells; Immunotherapy

Indexed keywords

CALNEXIN; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR CCR7; CYTOKINE; LENTIVIRUS VECTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; GENE TRANSFER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANTIBODY AFFINITY; ANTIGEN PRESENTATION; CALNEXIN; CANCER VACCINES; CELL PROLIFERATION; COCULTURE TECHNIQUES; COLONIC NEOPLASMS; DENDRITIC CELLS; GENETIC VECTORS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; RECEPTORS, CCR7; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 68249103400     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03067.x     Document Type: Article

References (39)

1. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001 106 : 255 8.
2. Ardavin C, Amigorena S, Reis e Sousa C. Dendritic cells: immunobiology and cancer immunotherapy. Immunity 2004 20 : 17 23.
3. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005 5 : 296 306. (Pubitemid 40516155)
4. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996 93 : 4102 7.
5. + T cells: optimal soldiers in the war against viruses and tumors. Immunol Res 2005 31 : 13 24.
6. Snyder JT, Alexander-Miller MA, Berzofskyl JA, Belyakov IM. Molecular mechanisms and biological significance of CTL avidity. Curr HIV Res 2003 1 : 287 94.
7. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999 162 : 2227 34.
8. + T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas. J Immunol 2000 164 : 191 200.
9. Derby M, Alexander-Miller M, Tse R, Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001 166 : 1690 7.
10. Gattinoni L, Powell DJ Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006 6 : 383 93.
11. + T cells. Immunol Rev 2002 186 : 221 33.
12. Seaman MS, Peyerl FW, Jackson SS, Lifton MA, Gorgone DA, Schmitz JE, Letvin NL. Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol 2004 78 : 206 15.
13. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005 102 : 9571 6.
14. + central memory T cells in protection from simian AIDS. J Immunol 2005 175 : 3502 7.
15. Chen X, He J, Chang L-J. Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells. Retrovirology 2004 1 : 37.
16. Wang B, He J, Liu C, Chang LJ. An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 2006 24 : 3477 89.
17. Pennisi E. Expanding the eukaryote's cast of chaperones. Science 1996 274 : 1613 4.
18. Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev 2004 5 : 781 91.
19. Bouvier M. Accessory proteins and the assembly of human class I MHC molecules: a molecular and structural perspective. Mol Immunol 2003 39 : 697 706.
20. Soti C, Pal C, Papp B, Csermely P. Molecular chaperones as regulatory elements of cellular networks. Curr Opin Cell Biol 2005 17 : 210 5.
21. Degen E, Williams DB. Participation of a novel 88-kD protein in the biogenesis of murine class I histocompatibility molecules. J Cell Biol 1991 112 : 1099 115.
22. Hochstenbach F, David V, Watkins S, Brenner MB. Endoplasmic reticulum resident protein of 90 kilodaltons associates with the T- and B-cell antigen receptors and major histocompatibility complex antigens during their assembly. Proc Natl Acad Sci USA 1992 89 : 4734 8.
23. Williams DB. Beyond lectins: the calnexin\calreticulin chaperone system of the endoplasmic reticulum. J Cell Sci 2006 4 : 615 23.
24. Molinari M, Eriksson KK, Calanca V, Galli C, Cresswell P, Michalak M, Helenius A. Contrasting functions of calreticulin and calnexin in glycoprotein folding and ER quality control. Mol Cell 2004 13 : 125 35.
25. Fukushima Y, Ohashi H, Wakui K, Nishida T, Oh-ishi T. A rapid method for starting a culture for the establishment of Epstein-Barr virus-transformed human lymphoblastoid cell lines. Jpn J Hum Genet 1992 37 : 149 50.
26. Zaiss A-K, Son S, Chang L-J. RNA 3′-readthrough of oncoretrovirus and lentivirus: implications in vector safety and efficacy. J Virol 2002 76 : 7209 19.
27. Han S, Wang B, Cotter MJ, Yang LJ, Zucali J, Moreb JS, Chang L-J. Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. Mol Ther 2008 16 : 269 79.
28. Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 2001 249 : 99 110.
29. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002 20 : 143 8.
30. Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005 174 : 5994 6004.
31. Yang S, Tsang KY, Schlom J. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin Cancer Res 2005 11 : 5603 15.
32. Dutoit V, Rubio-Godoy V, Doucey MA et al. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC\peptide multimer binding to TCR. J Immunol 2002 168 : 1167 71.
33. Echchakir H, Dorothee G, Vergnon I, Menez J, Chouaib S, Mami-Chouaib F. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc Natl Acad Sci USA 2002 99 : 9358 63.
34. Zeh HJ III., Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999 162 : 989 94.
35. Dudley ME, Nishimura MI, Holt AK, Rosenberg SA. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother 1999 22 : 288 98.
36. Yang L, Qin XF, Baltimore D, Van Parijs L. Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proc Natl Acad Sci USA 2002 99 : 6204 9.
37. Serbina NV, Jia T, Hohl TM, Pamer EG. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008 26 : 421 52.
38. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004 22 : 745 63.
39. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004 22 : 1136 51.